Edward Hospital opens pair of Quick Care Clinics within Jewel-Osco pharmacies
NAPERVILLE, Ill. — Edward Hospital on Thursday announced the opening of two Quick Care Clinics within a pair of Supervalu’s Jewel-Osco pharmacies.
"We are always seeking new opportunities to expand our services," stated Chris Dimos, Supervalu president of pharmacy and nonfoods merchandising. "Through this partnership, we will be able to offer our patients even more tools to help them manage their health and wellness needs."
Quick Care Clinic services are provided by board-certified family nurse practitioners and physician assistants of Edward Medical Group, the primary care practice of Edward Hospital.
BI launches hepatitis C website
RIDGEFIELD, Conn. — Drug maker Boehringer Ingelheim has created a website designed for patients with hepatitis C and advocates, the company said Friday.
BI announced the launch of HepCRedefined.com, which it describes as an online portal to help improve the lives of those living with the virus through education, information and understanding.
"The entire HCV community is in need of simple tools and resources to talk about the disease in an informed, supportive way," said Hepatitis Education Project executive director Michael Ninburg, who contributed to the website’s development. "There is information about HCV across the web, but HepCRedefined.com is designed to aggregate straightforward and accurate information in a single virtual destination."
FDA panel recommends approval for two Novo Nordisk insulin products
BAGSVÆRD, Denmark — A Food and Drug Administration panel has voted to support two experimental insulin treatments made by Novo Nordisk, the Danish drug maker said Thursday.
Novo Nordisk said the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee had voted 8-to-4 in favor of approval for insulin degludec and a combination treatment containing insulin degludec and insulin aspart.
The FDA is not bound by advisory committee votes when deciding whether or not to approve a drug, but usually follows them. However, the panel also voted unanimously to recommend that after approval, a post-marketing trial be conducted on the drugs to assess their effects on cardiovascular health.
"The positive vote from the advisory committee marks an important step towards making insulin degludec and insulin degludec-insulin aspart available to patients with diabetes in the US," Novo Nordisk EVP and chief science officer Mads Krogsgaard Thomsen said. "We look forward to completing the regulatory process with the agency, including the design of the post-approval cardiovascular outcomes trial."